Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
This study is investigating a new way to treat several types of cancer, including some head and neck, lung, and other solid tumours. It combines standard radiotherapy (radiation treatment) with a type of drug called PD-1/PD-L1 inhibitors. These drugs help your body's immune system fight cancer. We want to see how effective this combination treatment is, especially for cancers that have spread a little but can still be treated with radiation. A key part of the study is looking for 'biomarkers' – these are signs in your blood or tumour tissue that could help predict who will respond best to this treatment. This could lead to more personalised and effective cancer care in the future.
At a glance
What is this study about?
This study is designed to explore a new approach to tackling several types of cancer. Doctors already use special drugs called PD-1/PD-L1 inhibitors to treat cancers that have returned or spread. These drugs work by 'taking the brakes off' your immune system, allowing it to recognise and attack cancer cells more effectively. We also know that radiotherapy, which uses high-energy rays to kill cancer cells, is a common and effective treatment.
What makes this study important is that it's looking at using these two treatments – immune-boosting drugs and radiotherapy – together. Early research suggests that combining them might be even more effective, especially for certain Cancers where only a few spots have spread. By studying this combination, we hope to find better ways to fight these cancers and improve how well people respond to treatment.
Another big part of this research is about finding 'biomarkers'. These are like clues in your body, for example, changes in your blood or within the cancer tissue itself, that can tell us if a treatment is likely to work well for you. Our team has already seen promising signs that changes in immune cells in the blood could be good biomarkers. In this study, we'll be checking these ideas in many more patients. Finding reliable biomarkers would mean doctors could choose the most effective treatment for each person, making cancer care much more personal and targeted.
Key takeaways
- The study combines special immune-boosting drugs with radiotherapy for various cancers.
- It aims to find better ways to treat cancer and improve patient outcomes.
- Researchers are looking for 'biomarkers' to predict treatment success.
- Participation involves standard cancer treatment with extra monitoring.
- You can discuss with your doctor if this study might be right for you.
Who may be eligible?
To be part of this study, you would typically need to be an adult aged 18 or over. You would also need to have certain types of cancer, such as some head and neck cancers, lung cancers, or other solid tumours like oesophageal, bladder, kidney, some skin, or small cell lung cancers. Importantly, your doctor must think that treatment with a PD-1/PD-L1 inhibitor drug is suitable for you, based on current medical standards. You might have already had radiotherapy, or be planned to have it for some areas where your cancer has spread.
However, there are some reasons why you wouldn't be able to join. For example, if you have melanoma (a type of skin cancer), or if you are pregnant or breastfeeding and don't wish to use effective contraception. The study also cannot include people with serious drug or alcohol issues, or those who are unable to follow the study rules. If you are under care, unable to speak German, or are imprisoned, you would also not be able to participate. Most importantly, you need to be willing and able to cooperate with the study's requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have one of the specific cancer types mentioned (e.g., head and neck, lung, oesophageal, bladder, kidney, some skin, or small cell lung cancer)?
- Has your doctor said that a PD-1/PD-L1 inhibitor drug is suitable for your treatment?
- Are you able and willing to follow the study's instructions?
What does participation involve?
The detailed plan for taking part in this study is not fully described here. However, generally, it would involve receiving the combination of a PD-1/PD-L1 inhibitor drug and radiotherapy as advised by your medical team. You would have regular visits to the hospital for assessments, including blood tests to look for those important biomarkers, and possibly checks on your tumour tissue. These assessments would help the research team understand how your body is responding to the treatment and identify any potential side effects. The duration of your participation would depend on your cancer type and treatment plan, which your doctor would discuss with you.
Potential risks and benefits
Locations (1)
- Department of Radiation Oncology, Universitätsklinikum ErlangenVerified postcodeErlangen, Germany· Recruiting
Common questions
What kind of cancers is this study for?
It's for certain head and neck, lung, oesophageal, bladder, kidney, some skin cancers, and small cell lung cancers.
What are PD-1/PD-L1 inhibitors?
These are drugs that help your body's immune system fight cancer cells more effectively.
What does 'biomarker' mean?
A biomarker is a clue in your body, like a change in a blood test, that helps doctors predict how you might respond to a treatment.
Will I still get my usual treatment?
Yes, you will receive treatment based on standard medical care, but with the added research component of specific drugs and radiotherapy.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time without it affecting your normal medical care.
How to find out more
Markus Hecht, PD Dr.
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.